Naveen L. Pereira, M.D.

In order to facilitate future interventional trials, this study in participants with cardiomyopathy attributable to pathologic BAG3 mutations aims to comprehensively describe baseline characteristics and disease progression. This study will characterize circulating, imaging, and clinical biomarkers in BAG3 Dilated Cardiomyopathy (DCM) to understand biomarker correlations, as well as to the clinical course of BAG3 DCM over time.

This study is being done to develop a serum and tissue bank for future research of patients with heart failure, mechanical circulatory support and/or cardiothoracic transplants. This blood/tissue will be used for three principle purposes: (1) laboratory tests which will be available in the future but that are not currently available and which may be of benefit to the patient, (2) review of previous patient laboratory results made necessary by development of a new disease process by the patient, and (3) future unspecified research purposes.

To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.

The purpose of this study is to establish safety and preliminary effectiveness of treatment with MYK-491 in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants .

This study is an observational study to determine predictors of sudden cardiac death or appropriate ICD therapy in patients with non-ischemic cardiomyopathy. Patients will be followed for 36 months for the occurrence of sudden cardiac death

The purpose of this study is to develop an RNA-seq based peripheral blood assay predictive of inflammation/rejection on allograft biopsy in adult heart transplant recipients.